DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis
Mowbray, CE, Braillard, S, Glossop, PA, Whitlock, GA, Jacobs, RT, Speake, J, Pandi, B, Nare, B, Maes, L, Yardley, V, Freund, Y, Wall, RJ, Carvalho, S, Bello, D, Van den Kerkhof, M, Caljon, G, Gilbert, IH, Corpas-Lopez, V, Lukac, I, Patterson, S, Zuccotto, F and Wyllie, S.
2021.
DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis.
[Online].
ACS Publications, Washington, DC, USA.
Available from:
https://doi.org/10.1021/acs.jmedchem.1c01437.s004
Mowbray, CE, Braillard, S, Glossop, PA, Whitlock, GA, Jacobs, RT, Speake, J, Pandi, B, Nare, B, Maes, L, Yardley, V, Freund, Y, Wall, RJ, Carvalho, S, Bello, D, Van den Kerkhof, M, Caljon, G, Gilbert, IH, Corpas-Lopez, V, Lukac, I, Patterson, S, Zuccotto, F and Wyllie, S.
DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis
[Internet].
ACS Publications;
2021.
Available from:
https://doi.org/10.1021/acs.jmedchem.1c01437.s004
Mowbray, CE, Braillard, S, Glossop, PA, Whitlock, GA, Jacobs, RT, Speake, J, Pandi, B, Nare, B, Maes, L, Yardley, V, Freund, Y, Wall, RJ, Carvalho, S, Bello, D, Van den Kerkhof, M, Caljon, G, Gilbert, IH, Corpas-Lopez, V, Lukac, I, Patterson, S, Zuccotto, F and Wyllie, S
(2021).
DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis.
[Data Collection].
ACS Publications, Washington, DC, USA.
https://doi.org/10.1021/acs.jmedchem.1c01437.s004
Description
DNDI-6148 has been declared a preclinical candidate for the treatment of visceral leishmaniasis. This collection contains documentation (S1), string data for all compounds (S2), DNDI-6148 rat and dog pharmacokinetic data (S3) and Compound 23 docked into LdCPSF3 (S4). Files may be accessed through the Collection Record held on Figshare.
